



## A Better Way to Monitor Inflammatory Bowel Disease

### Why EUPHORIA?

Inflammatory Bowel Disease (IBD) is a chronic condition affecting more than 2.5 million people in Europe. People with IBD undergo flares of intestinal inflammation which may lead to surgical treatments, unemployment, sick leave and work disability. Adequate medical treatment including accurate diagnostics can reduce symptoms and prevent complications. However, endoscopic monitoring for the management of IBD is an invasive and ill-tolerated procedure.

Multispectral Optoacoustic Tomography (MSOT) has the unique ability to non-invasively measure perfusion and oxygenation as biomarkers of intestinal inflammation.

EUPHORIA is a Horizon 2020-funded project delivered by a consortium of leading European partners. The project aim is to optimize iThera Medical's handheld optoacoustic imaging platform for the assessment of inflammation in people with IBD and make it available to doctors and hospitals for routine use.

### What we do?

EUPHORIA is enabling iThera Medical and its partners to enter a new phase, moving from clinical research into routine care.

EUPHORIA will:

- Customize MSOT hardware to get the best possible results in IBD,
- Create better images of difficult-to-see tissues, using new software,
- Verify that MSOT is an attractive alternative to endoscopy in a substantial clinical trial,
- Get ready for the market by obtaining a CE mark,
- Conduct a rigorous health economic assessment to convince hospitals and healthcare payors that MSOT is an effective, reimbursable, validated clinical procedure, and
- Work with insurance companies and health agencies towards reimbursement approval.

### Why we do it?

EUPHORIA will enable wider access to MSOT technology for IBD patients. MSOT uses light and sound to create images. It is non-invasive, patient-friendly and less costly than MRI or CT. It has particular value in IBD, because of its ability to differentiate between many types of soft tissue and fluid, within the body - this enables more accurate diagnosis and more sensitive monitoring of IBD than other technologies. Successful execution of the clinical study will confirm its benefits to patients, doctors, hospitals, and ultimately also to payors, healthcare systems and society.

EUPHORIA is an EU-supported project which takes novel technology breakthroughs to the market – and the clinic.

Find out more: [www.euphoria2020.eu](http://www.euphoria2020.eu)

## Our European Consortium



*iThera Medical is the leading manufacturer worldwide of clinical optoacoustic devices.*

Dr. Patricia Smole  
Christian Wiest  
Dr. Amy Lin  
Jin He

Dr. Nina Dahlhaus  
Dr. Manuela Bung  
Dr. Philipp Bell



*University Hospital Erlangen, one of the largest IBD centers in Germany is ideally suited for clinical validation.*

Prof. Dr. Maximilian Waldner  
Prof. Dr. Markus Neurath

Dr. Ferdinand Knieling



*IMASONIC is a world leader in the development and manufacture of ultrasonic transducers.*

Bruno Klinguer  
Dr. Frédéric Brochin  
Dr. Mikael Wilm

Olivier Le Baron  
Gérard Fleury  
Dr. Etienne Coffy



*RAYFOS delivers specialized software for fast data acquisition and real time image processing.*

Vassilis Sarantos



*Pintail Limited is an expert management and communications SME.*

Ciaran Clissmann  
Danielle Nicholson

Sorcha O'Brien

### Media

Dr. Manuela Bung  
iThera Medical GmbH  
Zielstattstraße 13, 81379 München, Germany  
[manuela.bung@ithera-medical.com](mailto:manuela.bung@ithera-medical.com)

### Follow us:



[@euphoriah2020](https://twitter.com/euphoriah2020)



[@EUPHORIAH2020](https://www.facebook.com/EUPHORIAH2020)

